Innovating Proactive Protection Today for a Healthier Tomorrow
Formed by a dynamic team of scientists and clinicians from prestigious academic and industry backgrounds, InvisiShield is at the forefront of developing innovative preventive solutions for a wide range of existing and emerging respiratory viruses.
Central to our strategy is the prevention of infections by neutralizing airborne viruses at their very entry point – the nasal cavity. Our lead product candidate, a variant-proof Intranasal COVID-19 Preventative Spray - IS101, exemplifies this approach by defeating the virus where it invades.
Our proprietary technology platform can be applied to other illnesses caused by major respiratory viruses, such as the flu and RSV, as well as future emerging threats. As we continue to expand our research and product pipeline, our unwavering commitment to safeguarding global health remains at the heart of our mission.
Meet the InvisiShield Team
The Invisishield team is comprised of world-class scientists and medical professionals with diverse backgrounds and a shared passion for improving global public health. Our leadership brings together decades of experience in biomedical research, biotechnology and drug development, ensuring that our products meet the highest standards of quality, safety, and effectiveness. Our scientific advisors include world-renowned experts in virology, immunology, respiratory diseases and health regulations, who provide invaluable guidance in the development of our technologies.
Scientific Advisory Board
Eureka Therapeutics is a privately held clinical-stage biotechnology company focused on developing novel T-cell therapies to treat cancers. Having created InvisiShield’s IS101 intranasal COVID-19 preventive spray, Eureka separated its InvisiShield assets into InvisiShield Technologies Ltd., allowing each company to focus on its core missions. Eureka currently has two clinical assets in Phase I/II US trials in patients with advanced liver cancer.
Gladstone Institutes are an independent state-of-the-art biomedical research institution that empowers its world-class scientists to find new pathways to cures. We are closely partnering with Gladstone to develop intranasal preventatives against multiple types of airborne infections, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).
Getting Prepared for the Next Pandemic – the Best Defense Is a Good Offense
In a world where viral respiratory infections continue to pose significant challenges to global health, the call for a proactive approach to shield people from existing and novel viruses has never been more urgent.
The ongoing impact of COVID-19, the recurring annual influenza outbreaks, and the looming threat of new viruses that could trigger the next pandemic demonstrate that current preventive measures, such as lockdowns, social distancing and mask-wearing, are inefficient and in many cases ineffective tools for pandemic control.
Traditional medical solutions, such as vaccines, often target limited variant strains and generally act by preventing progression to disease rather than active infection. Vaccines prevent infection by the production of neutralizing antibodies weeks to months after vaccination, leaving the vaccinated person still susceptible to infection.
Recent studies have shown SARS-CoV-2 reinfections pose heightened risks of mortality, hospitalization, and long-term complications in multiple organ systems. Moreover, even mild SARS-CoV-2 infections can lead to long COVID, a spectrum of new or ongoing health complications following initial symptoms.
These challenges leave high-risk populations, such as the elderly and immunocompromised individuals, particularly vulnerable to these dangerous pathogens and in need of instant protection that does not rely solely on their own immune systems.
“An ounce of prevention is worth a pound of cure”
At InvisiShield, we believe that the best way to safeguard public health against airborne viral infections is through proactive protection. Our groundbreaking technology has enabled us to create transformative products that are designed to safeguard the well-being of millions.